Harnessing a revolution in biology for human health ®

Alnylam is developing RNAi therapeutics with an aim to meaningfully impact patient health . For more information on our clinical programs , including hereditary ATTR amyloidosis , hemophilia , acute intermittent porphyria and complement mediated diseases , visit us at Alnylam . com